IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.273
EU - Europa 6.228
AS - Asia 3.526
SA - Sud America 517
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 6
Totale 32.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.128
UA - Ucraina 2.104
SG - Singapore 1.845
DE - Germania 968
CN - Cina 956
IT - Italia 702
FI - Finlandia 649
RU - Federazione Russa 546
SE - Svezia 474
BR - Brasile 466
IE - Irlanda 367
TR - Turchia 183
KR - Corea 165
CA - Canada 126
GB - Regno Unito 114
FR - Francia 109
VN - Vietnam 89
HK - Hong Kong 78
IN - India 62
IR - Iran 43
AT - Austria 31
CZ - Repubblica Ceca 29
BE - Belgio 24
NL - Olanda 23
EU - Europa 18
TG - Togo 18
CO - Colombia 17
UZ - Uzbekistan 15
PL - Polonia 14
AR - Argentina 13
ZA - Sudafrica 13
EG - Egitto 12
JP - Giappone 11
RO - Romania 11
ES - Italia 9
MX - Messico 9
RS - Serbia 9
ID - Indonesia 8
IQ - Iraq 8
BD - Bangladesh 7
CH - Svizzera 7
LV - Lettonia 7
PK - Pakistan 7
BG - Bulgaria 6
EC - Ecuador 6
KG - Kirghizistan 6
AU - Australia 5
IL - Israele 5
HU - Ungheria 4
JO - Giordania 4
PE - Perù 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LK - Sri Lanka 3
LU - Lussemburgo 3
NO - Norvegia 3
OM - Oman 3
PY - Paraguay 3
TN - Tunisia 3
AL - Albania 2
BN - Brunei Darussalam 2
CL - Cile 2
EE - Estonia 2
GR - Grecia 2
HN - Honduras 2
KH - Cambogia 2
LB - Libano 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SA - Arabia Saudita 1
TH - Thailandia 1
TJ - Tagikistan 1
UY - Uruguay 1
Totale 32.617
Salva come PNG Salva come JPEG
Città #
Fairfield 2.992
Woodbridge 2.894
Houston 1.964
Ann Arbor 1.893
Jacksonville 1.415
Ashburn 1.293
Seattle 1.217
Wilmington 1.128
Chandler 1.108
Singapore 994
Cambridge 980
Dearborn 890
Boardman 485
Beijing 423
Princeton 382
Dublin 367
Udine 279
San Diego 188
Izmir 169
Seoul 151
Ogden 99
Ottawa 97
Norwalk 86
Dong Ket 84
Des Moines 78
Hong Kong 78
Hefei 62
Los Angeles 56
Nanjing 55
Redmond 50
Trieste 47
New York 45
Santa Clara 43
Kunming 41
Dallas 38
São Paulo 37
Milan 35
Guangzhou 32
Munich 32
Nuremberg 30
Regensburg 29
Simi Valley 29
Frankfurt am Main 27
Helsinki 25
Brussels 24
Jinan 23
Nanchang 23
Hangzhou 21
Saint Petersburg 21
Düsseldorf 20
Leawood 20
Toronto 20
Grafing 18
Lomé 18
Shenyang 17
Vienna 16
Phoenix 15
Venezia 15
Fuzhou 14
Tashkent 14
Wuhan 14
Andover 13
Bogotá 13
Chengdu 13
Falls Church 13
Rome 13
Shanghai 13
Augusta 12
Rio de Janeiro 12
San Mateo 12
Warsaw 12
Washington 12
Zanjan 12
Brno 11
Monmouth Junction 11
Prague 11
Ardabil 10
Lauterbourg 10
Zhengzhou 10
Chongqing 9
Duino-Aurisina 9
Hyderabad 9
London 9
Belgrade 8
Belo Horizonte 8
Brasília 8
Cairo 8
Indiana 8
Campinas 7
Curitiba 7
Hebei 7
Lappeenranta 7
Porto Alegre 7
Redwood City 7
Riga 7
Tokyo 7
Turku 7
Amsterdam 6
Bishkek 6
Caxias do Sul 6
Totale 23.130
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 245
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 207
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 190
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 156
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 156
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 155
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 151
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 149
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 149
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 149
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 145
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 145
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 144
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 144
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 143
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 141
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 141
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 140
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 139
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 139
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 137
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 137
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 137
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 136
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 135
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 134
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 133
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 133
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 132
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 131
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 131
Management of immune thrombocytopenia in elderly patients 131
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 130
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 130
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 129
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 128
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 127
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 126
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 126
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 126
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 125
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 125
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 124
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 123
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 123
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 122
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 122
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 122
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 122
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 121
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 121
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 121
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 120
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 120
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 120
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 120
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 120
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 119
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 118
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 118
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 117
A comparison of allografting with autografting for newly diagnosed myeloma 117
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 117
WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 116
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. 116
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 116
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 116
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 115
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 115
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 115
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 115
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 115
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 114
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 114
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 113
Wilms' tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes 113
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 113
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 113
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 112
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 112
Unexpected phenotype of a typical NPM1 mutant 112
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 112
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 112
Rituximab for the treatment of type II mixed cryoglobulinemia. 111
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-- analysis of 848 patients 111
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 111
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 111
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 111
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 111
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 111
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 110
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 110
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 110
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT 110
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 109
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 109
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 109
Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease 108
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 108
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 108
Totale 12.681
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.362
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020792 0 0 0 0 0 0 0 0 0 0 190 602
2020/20214.950 134 598 144 577 207 617 356 600 644 183 596 294
2021/20223.100 117 364 156 225 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20254.416 149 502 381 170 292 309 407 426 665 603 512 0
Totale 33.646